Advanced cancer trial recruits in 70 days

The BNT314-02 colorectal cancer study, which achieved a ‘European First’ – recruiting its first participant just 8 days after site activation – highlighting the UK’s capacity for rapid trial initiation. The entire process – from regulatory submission through review and set-up to recruitment – was completed in only 70 days, significantly outperforming the government’s 150-day metric.

Testing an innovative immunotherapy combination for patients with advanced cancer, this trial underscores how the UK is successfully removing barriers to innovation, ensuring that cutting-edge, experimental therapies reach the patients who need them most.